TP53 mutation predicts sensitivity to adjuvant gemcitabine in pancreatic cancer: Results from the CONKO-001 study

MLA

Jana K. Striefler, et al. “TP53 Mutation Predicts Sensitivity to Adjuvant Gemcitabine in Pancreatic Cancer: Results from the CONKO-001 Study.” Annals of Oncology, vol. 28, Sept. 2017, p. v251. EBSCOhost, https://doi.org/10.1093/annonc/mdx369.120.

APA

Jana K. Striefler, Hanno Riess, Hendrik Bläker, Uwe Pelzer, Rosa Schmuck, Carsten Denkert, Marianne Sinn, Anja Jühling, Bruno Valentin Sinn, Denise Treue, M Bahra, Sven Bischoff, Philipp Lohneis, Helmut Oettle, Jan Budczies, & Frederik Damm. (2017). TP53 mutation predicts sensitivity to adjuvant gemcitabine in pancreatic cancer: Results from the CONKO-001 study. Annals of Oncology, 28, v251. https://doi.org/10.1093/annonc/mdx369.120

Chicago

Jana K. Striefler, Hanno Riess, Hendrik Bläker, Uwe Pelzer, Rosa Schmuck, Carsten Denkert, Marianne Sinn, et al. 2017. “TP53 Mutation Predicts Sensitivity to Adjuvant Gemcitabine in Pancreatic Cancer: Results from the CONKO-001 Study.” Annals of Oncology 28 (September): v251. doi:10.1093/annonc/mdx369.120.